An Open-Label Study of the Safety of an Anti-CD38 Antibody Drug Conjugate (STI-6129) in Patients With AL Amyloidosis

NCT05692908 · clinicaltrials.gov ↗

PHASE1

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Stopped Sorrento Therapeutics filed for chapter 11 bankruptcy.

Conditions

Light Chain (AL) Amyloidosis

Interventions

BIOLOGICAL: STI-6129

Sponsor

Sorrento Therapeutics, Inc.